ERICD

Across TCGA pan-cancer cohorts, ERICD RNA is linked to patient survival in 21 of 34 cancer types, making it the most broadly survival-associated ERICD data layer.

The strongest signal is observed in brain lower grade glioma (LGG), where higher ERICD RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated ERICD expression acts as an unfavorable survival marker, although some lineages such as THCA and CESC show a favorable association.

LGG, ACC, and KIRP are the cancer types where ERICD RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LGG	DFS	Median	All	0.655	0.820	<.001	45	view →
ACC	OS	Median	All	0.453	0.762	.004	30	view →
KIRP	DFS	Median	All	0.794	0.917	.002	24	view →
LUSC	DFS	Quartile	All	0.312	0.503	.008	23	view →
KIRC	DFS	Quartile	II,III,IV	0.704	0.865	<.001	22	view →
STAD	DFS	Quartile	All	0.440	0.633	.009	17	view →
SARC	OS	Quartile	All	0.674	0.819	.010	13	view →
THCA	OS	Tertile	All	1.000	0.692	.007	12	view →
CESC	OS	Quartile	All	0.654	0.456	.047	8	view →
MESO	OS	Quartile	II,III,IV	0.512	0.694	.033	6	view →
OV	OS	Quartile	II,III,IV	0.882	0.763	.026	6	view →
LIHC	OS	Median	III,IV	0.244	0.443	.013	6	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 21 lineages.

ERICD–LGG (DFS)

Open the LGG breakdown →